Quick Answer
Bionano Genomics, Inc. reported Operating Income of -$33.34 million for fiscal year 2025.
Bionano Genomics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$33.34M | +67.9% |
| 2024 | -$103.98M | +51.7% |
| 2023 | -$215.25M | -63.4% |
| 2022 | -$131.70M | -70.8% |
| 2021 | -$77.10M | -100.0% |
| 2020 | -$38.55M | -49.0% |
| 2019 | -$25.87M | -26.7% |
| 2018 | -$20.42M | +12.1% |
| 2017 | -$23.22M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$8.54M | +80.6% | -9.5% |
| June 30, 2025 | -$7.80M | +54.2% | +7.9% |
| March 31, 2025 | -$8.46M | +72.8% | +80.7% |
| September 30, 2024 | -$43.90M | +61.2% | -158.0% |
| June 30, 2024 | -$17.02M | +56.6% | +45.3% |
| March 31, 2024 | -$31.12M | +17.8% | +72.5% |
| September 30, 2023 | -$113.21M | -252.1% | -188.5% |
| June 30, 2023 | -$39.24M | -22.3% | -3.7% |
- Bionano Genomics, Inc. showed an increase of +67.9% in Operating Income compared to the prior fiscal year.
- Over the 2017–2025 period, Bionano Genomics, Inc.’s operating income has declined by 43.6% (from -$23.22 million to -$33.34 million).
- The most recent figure is from Bionano Genomics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: